SE462140B - Foerfarande foer framstaellning av en loesning foer terapeutiskt bruk innehaallande nya flerkaerniga jaern(iii)blandkomplex med lakt obionsyraligand, som aktiv bestaandsdel - Google Patents
Foerfarande foer framstaellning av en loesning foer terapeutiskt bruk innehaallande nya flerkaerniga jaern(iii)blandkomplex med lakt obionsyraligand, som aktiv bestaandsdelInfo
- Publication number
- SE462140B SE462140B SE8305665A SE8305665A SE462140B SE 462140 B SE462140 B SE 462140B SE 8305665 A SE8305665 A SE 8305665A SE 8305665 A SE8305665 A SE 8305665A SE 462140 B SE462140 B SE 462140B
- Authority
- SE
- Sweden
- Prior art keywords
- iron
- solution
- iii
- preparation
- acetate
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 15
- 238000002360 preparation method Methods 0.000 title claims description 9
- 230000001225 therapeutic effect Effects 0.000 title 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 53
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 36
- 229910052742 iron Inorganic materials 0.000 claims description 24
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 claims description 12
- PVFSDGKDKFSOTB-UHFFFAOYSA-K iron(3+);triacetate Chemical compound [Fe+3].CC([O-])=O.CC([O-])=O.CC([O-])=O PVFSDGKDKFSOTB-UHFFFAOYSA-K 0.000 claims description 10
- 238000001256 steam distillation Methods 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 7
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- 229940099563 lactobionic acid Drugs 0.000 claims description 5
- 238000005292 vacuum distillation Methods 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 43
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 9
- 238000001669 Mossbauer spectrum Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- MSNWSDPPULHLDL-UHFFFAOYSA-K ferric hydroxide Chemical compound [OH-].[OH-].[OH-].[Fe+3] MSNWSDPPULHLDL-UHFFFAOYSA-K 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 3
- 239000013110 organic ligand Substances 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- MCDLETWIOVSGJT-UHFFFAOYSA-N acetic acid;iron Chemical compound [Fe].CC(O)=O.CC(O)=O MCDLETWIOVSGJT-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 150000002505 iron Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 238000003926 complexometric titration Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960004887 ferric hydroxide Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000004698 iron complex Chemical group 0.000 description 1
- 150000002506 iron compounds Chemical class 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000003918 potentiometric titration Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/02—Iron compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU823281A HU187167B (en) | 1982-10-15 | 1982-10-15 | Process for producing pharmaceutical solution of new type polynuclear iron/iii/ mixed complex activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| SE8305665D0 SE8305665D0 (sv) | 1983-10-14 |
| SE8305665L SE8305665L (sv) | 1984-04-16 |
| SE462140B true SE462140B (sv) | 1990-05-14 |
Family
ID=10963435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8305665A SE462140B (sv) | 1982-10-15 | 1983-10-14 | Foerfarande foer framstaellning av en loesning foer terapeutiskt bruk innehaallande nya flerkaerniga jaern(iii)blandkomplex med lakt obionsyraligand, som aktiv bestaandsdel |
Country Status (11)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3728814A1 (de) * | 1987-08-28 | 1989-03-30 | Lentia Gmbh | Loesung zur anwendung als spuelfluessigkeit in der zerstoerung von koerperfremden ablagerungen in menschlichen und tierischen geweben oder koerperhohlraeumen |
| DE4445772A1 (de) * | 1993-12-27 | 1995-06-29 | Loeser Thomas Dr Ing | Verfahren zur Ermittlung der Arzneimittelzusammensetzung |
| DE19712493A1 (de) * | 1997-03-25 | 1998-10-01 | Univ Karlsruhe | Pharmazeutische Zubereitung, enthaltend eine Eisen-Calcium-Polyolato-Verbindung und deren Verwendung |
| DE10249552A1 (de) | 2002-10-23 | 2004-05-13 | Vifor (International) Ag | Wasserlösliche Eisen-Kohlenhydrat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel |
| US20040170724A1 (en) * | 2003-02-28 | 2004-09-02 | Kraft Foods Holdings, Inc. | Mineral complexes of lactobionic acid and method of using for mineral fortification of food products |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE862482C (de) * | 1950-05-14 | 1953-01-12 | Merck Chem Fab E | Verfahren zur Darstellung haltbarer, injizierbarer Loesungen von Salzen des dreiwertigen Eisens |
| DE938502C (de) * | 1953-02-27 | 1956-02-02 | Benger S Ltd | Verfahren zur Herstellung einer kolloidalen Eisenzubereitung |
| GB978485A (en) * | 1960-10-26 | 1964-12-23 | Astra Apotekarnes Kem Fab | Iron preparations for intramuscular injection |
| DE1293144B (de) * | 1964-11-04 | 1969-04-24 | Hausmann Ag Labor | Verfahren zur Herstellung von Komplexverbindungen des Eisens mit Sorbit, Gluconsaeure und einem Oligosaccharid |
| DK122890B (da) * | 1964-12-29 | 1972-04-24 | J Reumert | Fremgangsmåde til fremstilling af ferrihydroxiddextrankomplekser. |
| DE1617463A1 (de) * | 1965-11-20 | 1971-04-08 | Bayer Ag | Verfahren zur Herstellung von injizierbaren kolloidalen Eisenzubereitungen |
| GB1149137A (en) * | 1966-10-28 | 1969-04-16 | H C F Porsche K G Ing | Screw outboard drive for boats |
| AT279048B (de) * | 1967-07-04 | 1970-02-25 | Pharmazeutische Fabrik Montavit Gmbh | Verfahren zur Herstellung neuer, löslicher und stabiler organischer Eisen(III)-Komplexverbindungen und Injektionslösungen davon |
| DE2527158A1 (de) * | 1975-06-18 | 1976-12-23 | Herz Eberhard | Arzneimittel zur behandlung von infektionskrankheiten und von nicht nachweisbar durch mikroorganismen ausgeloeste entzuendungen in der human- und veterinaermedizin |
| JPS6039681B2 (ja) * | 1976-01-01 | 1985-09-07 | 日本臓器製薬株式会社 | デキストリン・クエン酸・第二鉄多核複合体及び該複合体を含有する非経口用鉄剤 |
| GB2006243B (en) * | 1977-09-29 | 1982-07-14 | Atomic Energy Authority Uk | Compounds |
| DE3026868C2 (de) * | 1980-07-16 | 1986-03-13 | Laboratorien Hausmann AG, St. Gallen | Verfahren zur Herstellung von Eisen(III)hydroxid-Dextran-Komplexen und sie enthaltende pharmazeutische sterile wäßrige Lösung |
-
1982
- 1982-10-15 HU HU823281A patent/HU187167B/hu not_active IP Right Cessation
-
1983
- 1983-10-12 FI FI833707A patent/FI80830C/fi not_active IP Right Cessation
- 1983-10-12 AT AT0363983A patent/AT385655B/de not_active IP Right Cessation
- 1983-10-13 BE BE0/211691A patent/BE897980A/fr not_active IP Right Cessation
- 1983-10-14 FR FR8316377A patent/FR2534589B1/fr not_active Expired
- 1983-10-14 GB GB08327633A patent/GB2129821B/en not_active Expired
- 1983-10-14 DE DE19833337506 patent/DE3337506A1/de active Granted
- 1983-10-14 ES ES526481A patent/ES526481A0/es active Granted
- 1983-10-14 BG BG062649A patent/BG49708A3/xx unknown
- 1983-10-14 SE SE8305665A patent/SE462140B/sv not_active IP Right Cessation
- 1983-10-14 DK DK476583A patent/DK476583A/da not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ES8406196A1 (es) | 1984-08-01 |
| FI80830B (fi) | 1990-04-30 |
| BE897980A (fr) | 1984-01-30 |
| SE8305665L (sv) | 1984-04-16 |
| AT385655B (de) | 1988-05-10 |
| FI80830C (fi) | 1990-08-10 |
| ES526481A0 (es) | 1984-08-01 |
| GB2129821B (en) | 1986-02-19 |
| FI833707L (fi) | 1984-04-16 |
| DE3337506A1 (de) | 1984-04-19 |
| GB2129821A (en) | 1984-05-23 |
| FI833707A0 (fi) | 1983-10-12 |
| DE3337506C2 (enrdf_load_stackoverflow) | 1991-07-04 |
| FR2534589B1 (fr) | 1988-12-16 |
| FR2534589A1 (fr) | 1984-04-20 |
| SE8305665D0 (sv) | 1983-10-14 |
| GB8327633D0 (en) | 1983-11-16 |
| ATA363983A (de) | 1987-10-15 |
| DK476583A (da) | 1984-04-16 |
| DK476583D0 (da) | 1983-10-14 |
| BG49708A3 (bg) | 1992-01-15 |
| HU187167B (en) | 1985-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Harris et al. | Ferric ion sequestering agents. 6. The spectrophotometric and potentiometric evaluation of sulfonated tricatecholate ligands | |
| JP6655617B2 (ja) | Ｇｄ−ＤＯＴＡ金属錯体のメグルミン塩を含む製剤 | |
| SE462140B (sv) | Foerfarande foer framstaellning av en loesning foer terapeutiskt bruk innehaallande nya flerkaerniga jaern(iii)blandkomplex med lakt obionsyraligand, som aktiv bestaandsdel | |
| Terato et al. | Studies on iron absorption: I. The role of low molecular polymer in iron absorption | |
| EP0380950B1 (en) | Bismuth-containing composition | |
| Zabiszak et al. | New coordination compounds of citric acid and polyamines with lanthanide ions-potential application in monitoring the treatment of cancer diseases | |
| Voegtlin et al. | RATE OF EXCRETION OF ARSENICALS, A FACTOR | |
| CN105520955B (zh) | 一种羧基麦芽糖铁药用组合物及其制备方法 | |
| Djurdjević et al. | Solution equilibria between aluminum (III) ion and some fluoroquinolone family members. Spectroscopic and potentiometric study | |
| CN109091500A (zh) | 一种小儿复方电解质葡萄糖注射液及其制备方法 | |
| Inoue et al. | Magnetically different crystal modifications of copper (II) salicylate | |
| CN103394095B (zh) | 二氯-1,2-环己二胺合铂配合物及其制备方法 | |
| DE2259151A1 (de) | Verfahren zur herstellung eines antibiotikum-derivates | |
| Knoefel et al. | Renal tubular transport and molecular structure in the acetamidobenzoic acids | |
| RU2072993C1 (ru) | Способ получения соли 1, 4, 10, 13-тетраокса-7,16-диазациклооктадекан-n,n'-дималоновой кислоты | |
| Djurdjevic et al. | Solution Equilibria between Aluminum (III) Ion and L‐histidine or L‐tyrosine | |
| Гуляєв et al. | NOVEL COPPER (II) CHELATE COMPLEX WITH TRIS-(HYDROXYMETHYL)-AMINOMETHANE: STRUCTURAL CHARACTERIZATION AND ANTIBACTERIAL ACTIVITY | |
| Camper et al. | Sorption of substituted phenylamides onto bovine serum albumin | |
| RU2063238C1 (ru) | Способ получения средства, обладающего противоопухолевой активностью | |
| DE255030C (enrdf_load_stackoverflow) | ||
| RU2056845C1 (ru) | Стимуляторы желчеотделения и моторной функции кишечника у животных | |
| Mellor et al. | Effects of antibiotic treatment on the composition of sheep foetal fluids | |
| SU713152A1 (ru) | Свинцова соль @ -амино- @ -фенилпропионовой кислоты, про вл юща канцеролитическое действие | |
| JPH0150235B2 (enrdf_load_stackoverflow) | ||
| US1069954A (en) | Therapeutic compound and process of making the same. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |
Ref document number: 8305665-5 Effective date: 19920510 Format of ref document f/p: F |